Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Other Operating Expenses (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Other Operating Expenses data on record, last reported at $1.9 million in Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 98.03% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $9.6 million, down 90.86%, while the annual FY2025 figure was $9.6 million, 90.86% down from the prior year.
  • Other Operating Expenses reached $1.9 million in Q4 2025 per ACRS's latest filing, down from $2.5 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $94.9 million in Q4 2024 and bottomed at -$13.2 million in Q4 2023.
  • Average Other Operating Expenses over 5 years is $7.9 million, with a median of $2.9 million recorded in 2024.
  • The widest YoY moves for Other Operating Expenses: up 2475.56% in 2023, down 253.74% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $3.3 million in 2021, then soared by 157.21% to $8.6 million in 2022, then crashed by 253.74% to -$13.2 million in 2023, then soared by 816.65% to $94.9 million in 2024, then tumbled by 98.03% to $1.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $1.9 million in Q4 2025, $2.5 million in Q3 2025, and $3.4 million in Q2 2025.